Summarized by Masters of Longevity from FierceBiotech - Biotech.
Retatrutide data are the focus of an article that walks readers through a detailed phase 3 trial report and what it could mean for obesity treatment, highlighting the type of evidence and implications to watch.
Key Takeaways
- Retatrutide produced substantial weight loss, with over one-third of high-dose participants losing at least 25% body weight.
- Higher doses of the triple-agonist were associated with larger average weight reductions in adults with obesity.
